The European League Against Rheumatism (EULAR) has developed recommendations for the management of rheumatoid arthritis (RA) using synthetic and biological disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). These recommendations aim to provide a European consensus on RA management, based on evidence and expert opinion. The recommendations cover general aspects such as remission/low disease activity as treatment goals, the preference for methotrexate monotherapy with or without GCs, the use of biological agents in patients who have failed synthetic DMARDs and tumor necrosis factor inhibitors, and cost-effectiveness. The recommendations are structured into five main areas: synthetic DMARDs as monotherapy or in combination without GCs, GCs alone and in combination with synthetic DMARDs, biological DMARDs, treatment strategies, and economic issues. The recommendations are intended to inform rheumatologists, patients, and stakeholders about optimal RA management, based on evidence and expert opinion. The task force emphasized the importance of early initiation of DMARD treatment, the role of GCs, and the need for a strategic treatment approach to achieve remission or low disease activity. The recommendations also highlight the importance of considering patient-specific factors when adjusting treatment strategies.The European League Against Rheumatism (EULAR) has developed recommendations for the management of rheumatoid arthritis (RA) using synthetic and biological disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). These recommendations aim to provide a European consensus on RA management, based on evidence and expert opinion. The recommendations cover general aspects such as remission/low disease activity as treatment goals, the preference for methotrexate monotherapy with or without GCs, the use of biological agents in patients who have failed synthetic DMARDs and tumor necrosis factor inhibitors, and cost-effectiveness. The recommendations are structured into five main areas: synthetic DMARDs as monotherapy or in combination without GCs, GCs alone and in combination with synthetic DMARDs, biological DMARDs, treatment strategies, and economic issues. The recommendations are intended to inform rheumatologists, patients, and stakeholders about optimal RA management, based on evidence and expert opinion. The task force emphasized the importance of early initiation of DMARD treatment, the role of GCs, and the need for a strategic treatment approach to achieve remission or low disease activity. The recommendations also highlight the importance of considering patient-specific factors when adjusting treatment strategies.